ClinicalTrials.gg
CompletedNCT06697899Updated May 16, 2025

TGRX-678 Phase I Oral Pharmacokinetic Study

A Phase 1 interventional study of TGRX-678 in Chronic Myeloid Leukemia, sponsored by Shenzhen TargetRx, Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-16.

Sponsored by Shenzhen TargetRx, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China — 11 open to participants now, 14 under way, 2 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · China.

Enrollment
25th of 37
76 · median 144
Started
2024
with 3 others
Phase 1
9 of 49
1 open now
Registered
43rd of 49
by date
Lead sponsor
3 of 49
Shenzhen TargetRx, Inc.

Among the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, this one is the 25th largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2024, is one of 9 in phase 1, and was the 43rd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

11 of the 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in China, or all of them as a file.
02

Study summary

A study evaluating the effects of food intake on the pharmacokinetic (PK) profiles of TGRX-678

Read the detailed description

This study is designed as single-center, single-dose, randomized, open-label and parallel-comparison to evaluate food effect on PK profile of TGRX-678 in healthy subjects. Safety and tolerability of the drug is also evaluated during study.

03

Conditions studied

  • Chronic Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants, male or female
  • Age between 18 and 45 (both inclusive)
  • Body Weight: male ≥ 50 kg, female ≥ 45 kg; (BMI) between 19.0 and 26.0 kg/m\^2 (both inclusive)
  • Signing informed concent at own will
  • Able to communicate with researcher and able to complete study per protocol instruction

Exclusion criteria

Exclusion Criteria:

  • abnormal results in lab test, physical exam or 12-lead (ECG) test
  • Positive results for , , or Syphilis
  • elongation as indicated by 12-lead ECG test during screening period
  • Use of any medication that could impact enzyme activities within 30 days prior to Screening period
  • Use of any medication within 14 days of first dose of the drug
  • Vaccinated within 30 days of first dose of the investigational drug, or planning to be vaccinated during study
  • History of instrumental cardiovascular diseases
  • Received major surgery within 6 months prior to Screening, or with surgical wounds not completely healed
  • History of any severe disease or conditions that could affect study results per investigator's discretion
  • History of allergic conditions or is allergic to components of the investigational drug
  • Having conditions that could affect drug absorption or difficulties to swallow
  • History of smoking of >5 cigarettes per day within 3 months prior to screening, or cannot stop tabacco using during study
  • History of alcohol abuse, or alcohol consumption of >14 unit alcohol within 3 months prior to screening
  • History of substance use, or tested positive for drug test during screening
  • History of specific food (i.e., grapefruit, mango) consumption, or/and large tea/coffee/caffeinated drink/grapefruit product intake of > 8 cups per day, within 2 weeks prior to first dose
  • Having special dietary requirement and cannot comply with food requirement of the study
  • Pregnant or breastfeeding female, or tested positive in pregnancy test
  • History of unprotected sexual activities within 1 month prior to screening
  • Having plans for pregnancy during the study and within 6 months after study completion; or not agreeing to take strict measures during study and within 6 months after study completion
  • History of blood loss/ blood donation of ≥ 400 mL within 3 months prior to screening, or planning to donate blood within 1 month after study completion
  • Any reasons that is deemed unsuitable for study participation as determined by investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Fasting

    Participants take TGRX-678 under fasting state

    Drug: TGRX-678

  • Experimental
    Low-fat Diet

    Participants take TGRX-678 after low-fat meal intake

    Drug: TGRX-678

  • Experimental
    High-fat Diet

    Participants take TGRX-678 after high-fat meal intake

    Drug: TGRX-678

Interventions

  • All participants are given TGRX-678 orally at 240 mg

06

What researchers measure

Primary outcomes

  1. Plasma Tmax

    Time to maximum concentration (Tmax) of TGRX-678 measured in plasma

    Time frame: During Treatment period (Day 1 to Day 43)

  2. Plasma Tlag

    Time between drug administration to drug absorption (Tlag) as indicated by TGRX-678 plasma concentration

    Time frame: During Treatment period (Day 1 to Day 43)

  3. Plasma Cmax

    Maximum concentration (Cmax) of TGRX-678 measured in plasma

    Time frame: During Treatment period (Day 1 to Day 43)

  4. Plasma AUC(0-t)

    Area Under drug concentration-time curve (AUC) from time 0 to last measureable timepoint for TGRX-678 as measured in plasma

    Time frame: During Treatment period (Day 1 to Day 43)

  5. Plasma AUC(0-inf)

    Area Under drug concentration-time curve from time 0 to infinity for TGRX-678 as measured in plasma

    Time frame: During Treatment period (Day 1 to Day 43)

  6. AUC(%Extrap)

    Calculated percentage of Area under curve for AUC(0-inf) that is from last measurable timepoint ot infinity, calculated based on TGRX-678 plasma concentration over time curve.

    Time frame: During Treatment period (Day 1 to Day 43)

  7. Half Life (T1/2)

    Time for TGRX-678 to decrease from maximum plasma concentration to half of maximum plasma concentration

    Time frame: During Treatment period (Day 1 to Day 43)

  8. Plasma volume of distribution (Vz/F)

    Apparent volume of distribution of TGRX-678 in plasma

    Time frame: During Treatment period (Day 1 to Day 43)

  9. Plasma clearance (CL/F)

    Apparent clearance of TGRX-678 in plasma

    Time frame: During Treatment period (Day 1 to Day 43)

Secondary outcomes

  1. Adverse Events (AE)

    To record adverse events to participants during study participation

    Time frame: Starting from consent signing and until end of Treatment period (Day 1 to Day 43)

07

Study locations

1 site
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Jan 2025, 1 month.

Of 56 phase 1 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 95. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
Nov 24, 2024
Primary completionActual
Jan 6, 2025
CompletionActual
Feb 20, 2025
Last update
May 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06697899
Lead sponsor
Shenzhen TargetRx, Inc.
Responsible party
Sponsor
First posted
Nov 20, 2024
Start date
Nov 24, 2024
Primary completion
Jan 6, 2025
Completion
Feb 20, 2025
Last update
May 16, 2025

Study contacts

Juan Li, MD
principal investigator · Nanjing Drug Tower Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meribatinib

Start the discussion